ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

NSABP Submits Appeal To NIH To Reverse Cancellation Of P-4 Chemoprevention Trial.

August 10, 2007

NCI CTEP Approved Trials For the Month of January

January 31, 2014

In Brief: Hawaii Study finds No Increase Risk for Large Bowell Cancer From High Intake Of Saturated Fat

October 12, 1984

Hammer Says President’s Science Advisory to Ask For FY 1985 Supplemental Appropriations for NCI

March 1, 1985

PhRMA Tightens DTC Restrictions, But Dingell Says It’s Not Enough.

December 12, 2008

DCBD Board Okays Concept Of Program Announcement To Stimulate Human Monoclonal Antibody Research

June 4, 1982